Neil Mehta, MD
Hepatology · San Francisco, CANPI 1235293325
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,207 of the $60,420 with a category attached, or 63.2%. 10 manufacturers reported payments, led by Merck at 36.3% of the total. 2025 is the largest year on record at $25,025, more than ten times the $1,296 reported in 2019.
Across 38 payments — averaging $1590.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$22K
- Fujifilm Healthcare Americas Corporation$18K
- Boston Scientific$8K
- Sirtex Medical Inc$4K
- AstraZeneca$4K
- Genentech, Inc.$3K
- plus $3K from 4 others
Across 1 payment — averaging $48,515 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fujifilm Healthcare Americas Corporation$49K
What the payments were for
- Consulting fees$38,20763%
- Speaking & faculty fees$17,68929%
- Travel & lodging$2,5894%
- Food & beverage$1,9353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $21,960 |
| Fujifilm Healthcare Americas Corporation | 17 | $17,795 |
| Boston Scientific | 3 | $7,690 |
| Sirtex Medical Inc | 2 | $3,650 |
| AstraZeneca | 6 | $3,624 |
| Genentech, Inc. | 3 | $2,714 |
| Exelixis Inc. | 1 | $1,650 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 2 | $1,202 |
| Biocompatibles, Inc. | 1 | $94 |
| Genentech USA, Inc. | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- uTASWako AFP-L3$12,181
- General - Interventional Oncology$7,690
- SIR-Spheres Microspheres$3,650
- IMFINZI$3,466
- Cabometyx$1,650
- Wako HCC Biomarker(s) DCP and AFP-L3$1,202
How this compares
$60,420 in reported general payments places this provider in the 70th percentile of 36 hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 68 | $117,962 |
| XifaxanRifaximin | 26 | $82,775 |
| Ursodiol | 64 | $15,649 |
| Entecavir | 83 | $14,085 |
| Mercaptopurine | 15 | $463 |
| Azathioprine | 15 | $408 |
| Carvedilol | 37 | $180 |
| Spironolactone | 25 | $86 |
| Furosemide | 32 | $85 |
Paid to pharmacies, not to this prescriber.
Other hepatology in San Francisco
- Maurizio BonaciniSan Francisco$88K
- Monika SarkarSan Francisco$10K
- Courtney ShermanSan Francisco$206
- Gabrielle JutrasSan Francisco$123
- Robert GishFolsom$1.9M
- Edward MenaPasadena$624K
- Walid AyoubWest Hollywood$416K
- Tarek HassaneinCoronado$278K
- Ke-Qin HuOrange$239K
- Vinay SundaramLos Angeles$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.